Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Bausch Health Companies Inc. (BHC)

Bausch Health Q2 revenue rises 13% to $2.85 billion; raises 2026 guidance

Positive Impact 4 of 5 earnings Written later

Bausch Health reported second-quarter 2026 revenue of $2.85 billion, up 13% from a year earlier, with GAAP diluted earnings per share of $0.68 versus $0.40 and adjusted diluted earnings per share of $1.26 versus $0.90. The company raised its full-year 2026 revenue, Adjusted EBITDA and Adjusted Cash Flows from Operations guidance for Bausch Health excluding Bausch + Lomb, which points to stronger results for shareholders.

Key points

  • Q2 2026 consolidated revenue was $2.85 billion, up 13% on a reported basis and 11% organic, versus $2.53 billion a year earlier
  • GAAP net income attributable to Bausch Health was $258 million, compared with $148 million in Q2 2025
  • Consolidated Adjusted EBITDA was $1,075 million, up from $842 million, and operating income was $740 million, up from $444 million
  • Full-year 2026 Bausch Health (excluding Bausch + Lomb) revenue guidance is $10.790 billion to $11.040 billion, with Adjusted EBITDA guidance of $4.050 billion to $4.175 billion

The filing

CompanyBausch Health Companies Inc. (BHC)
Form8-K, current report
Filed with the SECJul 29, 2026, 4:11 PM ET
Accession number0000885590-26-000105

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 29, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.